title: Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
abstract: Sirolimus is an effective agent used in graft-versus-host disease (GVHD) prophylaxis after allogeneic transplantation. It also has antiproliferative effects on vascular endothelium when used to coat coronary artery stents. We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrospectively reviewed the records of 488 patients to determine the association between sirolimus and VOD. When used with cyclophosphamide/total body irradiation (Cy/TBI) conditioning, sirolimus is associated with an increased incidence of VOD (OR 2.35, P = .005). The concomitant use of methotrexate further increased this rate (OR 3.23, P < .001), while sirolimus without methotrexate was not associated with an increased risk of VOD (OR 1.55, P = .33). Mortality after VOD diagnosis was unaffected, and overall treatment-related mortality was lowest when sirolimus was used without methotrexate. Similar findings were noted in matched, related, and unrelated as well as mismatched donor subgroups. When used with busulfan-based conditioning, sirolimus use was associated with an even higher rate of VOD (OR 8.8, P = .008). Our findings suggest that sirolimus use is associated with VOD after TBI-based transplantation when used with methotrexate after transplantation. Sirolimus-based GVHD prophylaxis without methotrexate is associated with the greatest overall survival. Myeloablative doses of busulfan should not be used with sirolimus-based immunosuppression.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. corey_cutler@dfci.harvard.edu
authors.forename: Corey
authors.initials: C
authors.lastname: Cutler
authors.forename: Kristen
authors.initials: K
authors.lastname: Stevenson
authors.forename: Haesook T
authors.initials: HT
authors.lastname: Kim
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
authors.forename: Vincent T
authors.initials: VT
authors.lastname: Ho
authors.forename: Erica
authors.initials: E
authors.lastname: Linden
authors.forename: Carolyn
authors.initials: C
authors.lastname: Revta
authors.forename: Ruth
authors.initials: R
authors.lastname: Ebert
authors.forename: Diane
authors.initials: D
authors.lastname: Warren
authors.forename: Sung
authors.initials: S
authors.lastname: Choi
authors.forename: John
authors.initials: J
authors.lastname: Koreth
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
authors.forename: Edwin
authors.initials: E
authors.lastname: Alyea
authors.forename: Shelly
authors.initials: S
authors.lastname: Carter
authors.forename: Mary
authors.initials: M
authors.lastname: Horowitz
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
authors.forename: Robert
authors.initials: R
authors.lastname: Soiffer
mesh_terms: D000293:Adolescent; D000328:Adult; D004338:Drug Combinations; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D007166:Immunosuppressive Agents; D020123:Sirolimus
references.citation: J Cardiovasc Pharmacol. 2006 Dec;48(6):286-92
references.pmid: 17204907
references.citation: Transplantation. 1999 Apr 15;67(7):1036-42
references.pmid: 10221490
references.citation: Am J Transplant. 2005 Oct;5(10):2441-7
references.pmid: 16162193
references.citation: Bone Marrow Transplant. 1996 Feb;17(2):225-30
references.pmid: 8640171
references.citation: Clin Chim Acta. 2006 Jun;368(1-2):93-8
references.pmid: 16448639
references.citation: Br J Haematol. 2002 Sep;118(4):1087-94
references.pmid: 12199790
references.citation: FASEB J. 2002 Jun;16(8):771-80
references.pmid: 12039858
references.citation: Blood. 1994 May 1;83(9):2723-30
references.pmid: 8167351
references.citation: Liver Transpl. 2003 May;9(5):463-8
references.pmid: 12740787
references.citation: Transplant Proc. 2003 May;35(3 Suppl):193S-200S
references.pmid: 12742496
references.citation: Ann Hematol. 2005 May;84(5):321-30
references.pmid: 15580502
references.citation: Blood. 2002 Dec 15;100(13):4337-43
references.pmid: 12393437
references.citation: Bone Marrow Transplant. 2008 Feb;41(3):229-37
references.pmid: 17994121
references.citation: Bone Marrow Transplant. 1996 Jan;17(1):75-80
references.pmid: 8673059
references.citation: Biol Blood Marrow Transplant. 2002;8(9):493-500
references.pmid: 12374454
references.citation: Transplant Proc. 2003 May;35(3 Suppl):231S-233S
references.pmid: 12742501
references.citation: Circulation. 2005 Feb 22;111(7):926-31
references.pmid: 15710768
references.citation: Pediatr Blood Cancer. 2008 Apr;50(4):831-2
references.pmid: 18286502
references.citation: Transplantation. 2008 Jan 15;85(1):125-34
references.pmid: 18192922
references.citation: Br J Cancer. 2006 May 8;94(9):1226-30
references.pmid: 16622453
references.citation: Bone Marrow Transplant. 2004 Jan;33(2):189-95
references.pmid: 14661036
references.citation: Bone Marrow Transplant. 2001 Jun;27(11):1121-4
references.pmid: 11551021
references.citation: Transplantation. 1987 Dec;44(6):778-83
references.pmid: 3321587
references.citation: Atherosclerosis. 2006 Dec;189(2):288-96
references.pmid: 16455087
references.citation: Curr Opin Nephrol Hypertens. 2002 Nov;11(6):603-7
references.pmid: 12394605
references.citation: Blood. 2007 Apr 1;109(7):3108-14
references.pmid: 17138818
references.citation: Biol Blood Marrow Transplant. 2004 May;10(5):347-54
references.pmid: 15111934
references.citation: Liver Transpl. 2001 Aug;7(8):701-8
references.pmid: 11510015
references.citation: N Engl J Med. 2003 Oct 2;349(14):1307-9
references.pmid: 14523135
references.citation: Transplantation. 1999 Feb 27;67(4):505-9
references.pmid: 10071017
references.citation: Transplant Proc. 2003 May;35(3 Suppl):201S-208S
references.pmid: 12742497
references.citation: Blood. 2007 Jul 15;110(2):490-500
references.pmid: 17392502
references.citation: Blood. 2003 Sep 1;102(5):1601-5
references.pmid: 12730113
references.citation: Blood. 2003 Sep 1;102(5):1578-82
references.pmid: 12738663
references.citation: Gastroenterology. 1999 Nov;117(5):1198-204
references.pmid: 10535884
references.citation: Transplantation. 2004 Jan 27;77(2):252-8
references.pmid: 14742990
references.citation: Pharmacol Toxicol. 2001 Sep;89(3):133-9
references.pmid: 11589784
references.citation: Biol Blood Marrow Transplant. 2005 May;11(5):383-8
references.pmid: 15846292
references.citation: Bone Marrow Transplant. 1996 Aug;18(2):383-8
references.pmid: 8864450
references.citation: Circ J. 2007 Feb;71(2):220-5
references.pmid: 17251671
references.citation: Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7
references.pmid: 15983555